New Targets in Inflammation Inhibitors of COX-2 or Adhesion Molecules Proceedings of a conference held on April 15–16, 1996, in New Orleans, USA, supported by an educational grant from Boehringer Ingelheim

For the past 100 years the mainstay of therapy for rheumatoid arthritis (RA) has been aspirin or other drugs of the non-steroid anti-inflammatory group. In 1971 Vane pro­ posed that both the beneficial and toxic actions of these drugs was through inhibition of prostaglandin synthesis. The recent dis...

Full description

Bibliographic Details
Other Authors: Bazan, N. (Editor), Botting, Jack H. (Editor), Vane, Sir John R. (Editor)
Format: eBook
Language:English
Published: Dordrecht Springer Netherlands 1996, 1996
Edition:1st ed. 1996
Subjects:
Online Access:
Collection: Springer Book Archives -2004 - Collection details see MPG.ReNa
Table of Contents:
  • 1 The history of anti-inflammatory drugs and their mechanism of action
  • 2 Structure of prostaglandin H2 synthase-1 (COX-1) and its NSAID binding sites
  • 3 Differential inhibition of cyclooxygenases 1 and 2 by NSAIDs
  • 4 Blockade of inflammatory hyperalgesia and cyclooxygenase-2
  • 5 Brain COX-2 in experimental models of epilepsy and stroke: signalling pathways leading to enhanced expression
  • 6 New highly selective cyclooxygenase-2 inhibitors
  • 7 Characteristics of cyclooxygenase-1 and cyclooxygenase-2-deficient mice
  • 8 X-ray crystal structure of human cyclooxygenase-2
  • 9 Risk of gastrointestinal side effects caused by non-steroid anti-inflammatory drugs (NSAIDs)
  • 10 Expression and regulation of cyclooxygenase-2 in synovial tissues of arthritic patients
  • 11 Differential target tissue presentation and COX-1/COX-2 inhibition by non-steroid anti-inflammatory drugs: a rationale for a new classification
  • 12 Clinical experience with meloxicam, a selective COX-2 inhibitor
  • 13 Enzymatic regulation of the prostaglandin response in a human model of inflammation
  • 14 Cyclooxygenase-2 and intestinal cancer
  • 15 Cytokines and adhesion molecules in the lung inflammatory response
  • 16 Adhesion molecules as targets for therapy in rheumatoid arthritis